These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1817 related articles for article (PubMed ID: 33712752)

  • 1. COVID antibody treatments show promise for preventing severe disease.
    Ledford H
    Nature; 2021 Mar; 591(7851):513-514. PubMed ID: 33712752
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2.
    Liu H; Zhang Q; Wei P; Chen Z; Aviszus K; Yang J; Downing W; Jiang C; Liang B; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G
    Cell Res; 2021 Jun; 31(6):720-722. PubMed ID: 33893398
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
    Suganya S; Divya S; Parani M
    Rev Med Virol; 2021 May; 31(3):e2174. PubMed ID: 32965078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
    Starr TN; Greaney AJ; Addetia A; Hannon WW; Choudhary MC; Dingens AS; Li JZ; Bloom JD
    Science; 2021 Feb; 371(6531):850-854. PubMed ID: 33495308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
    Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
    Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19.
    Razonable RR; Ganesh R; Bierle DM
    Mayo Clin Proc; 2022 Jan; 97(1):26-30. PubMed ID: 34996562
    [No Abstract]   [Full Text] [Related]  

  • 10. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
    Hoffmann M; Hofmann-Winkler H; Krüger N; Kempf A; Nehlmeier I; Graichen L; Arora P; Sidarovich A; Moldenhauer AS; Winkler MS; Schulz S; Jäck HM; Stankov MV; Behrens GMN; Pöhlmann S
    Cell Rep; 2021 Jul; 36(3):109415. PubMed ID: 34270919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor markers as an entry for SARS-CoV-2 infection?
    Xia P; Dubrovska A
    FEBS J; 2020 Sep; 287(17):3677-3680. PubMed ID: 32738184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials.
    Kow CS; Ramachandram DS; Hasan SS
    Immunopharmacol Immunotoxicol; 2022 Feb; 44(1):28-34. PubMed ID: 34762561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
    Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
    PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development.
    Wang MY; Zhao R; Gao LJ; Gao XF; Wang DP; Cao JM
    Front Cell Infect Microbiol; 2020; 10():587269. PubMed ID: 33324574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants.
    Lee S; Jang S; Kang J; Park SB; Han YW; Nam H; Kim M; Lee J; Cho KJ; Kim J; Oh M; Ryu J; Seok JH; Kim Y; Lee JB; Park MS; Kim YS; Park H; Kim DS
    Front Immunol; 2021; 12():778829. PubMed ID: 34868052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review.
    Tiecco G; Storti S; Degli Antoni M; Focà E; Castelli F; Quiros-Roldan E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.
    Rawat P; Sharma D; Srivastava A; Janakiraman V; Gromiha MM
    Sci Rep; 2021 May; 11(1):10220. PubMed ID: 33986382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.